Favorites Sign in

One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
  1. Home
  2. Companies
  3. LifeMD
  4. Financial Statements
LifeMD logo
LifeMD LFMD
$ 2.11 -1.63%
report update icon

Quarterly report 2026-Q2
added 08-05-2026

LifeMD Financial Statements 2025-2011 | LFMD

Annual Financial Statements LifeMD

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

 		176 M 161 M 270 M 37.8 M 105 M 297 M 6.43 M 7.07 M 11.7 M 8.37 M 4.62 M 5.47 M 7.93 M 4.68 M 3.81 M

Shares

 		45.1 M 41.2 M 33.9 M 31 M 27 M 14.3 M 9.9 M 8.84 M 8.35 M 6.7 M 6.16 M 6.07 M 5.88 M 5.5 M 4.48 M

Historical Prices

 		3.91 3.91 7.95 1.22 3.87 6.53 0.6 0.7 1.7 1.3 0.6 0.5 1.3 0.8 1

Net Income

 		-11.2 M 24.5 M 17.8 M -45.5 M -60.9 M -58.6 M -3.14 M -1.24 M -1.21 M -1.11 M -62 K -460 K -268 K -446 K -503 K

Revenue

 		194 M 155 M 153 M 119 M 92.9 M 37.3 M 12.5 M 8.32 M 5.05 M 5.24 M 1.22 M 714 K 808 K 674 K 744 K

Cost of Revenue

 		27.7 M 21.4 M 18.9 M 18.7 M 18 M 8.86 M 2.53 M 2 M 1.02 M 1.95 M 248 K 173 K 181 K 200 K -

Gross Profit

 		166 M 133 M 134 M 100 M 74.9 M 28.4 M 9.2 M 6.36 M 3.57 M 3.29 M 971 K 541 K 627 K 548 K 503 K

Operating Income

 		-7.67 M -20.4 M -14.5 M -43.4 M -54.3 M -57.8 M -2.89 M -2.06 M -1.23 M -1.17 M -262 K -531 K -546 K -540 K -

Interest Expense

 		1.36 M 2.18 M 2.6 M 1.28 M 3.02 M 1.67 M 761 K 354 K 101 K 48.6 K 37.5 K 4.68 K 3.38 K 3.37 K -

EBITDA

 		-6.8 M -19.9 M -14.3 M -43.3 M -54.3 M -57.4 M -2.55 M -1.86 M -1.07 M -1.17 M -218 K -474 K -489 K -483 K -520 K

Operating Expenses

 		174 M 154 M 148 M 144 M 129 M 86.2 M 12.1 M 8.41 M 4.64 M 4.47 M 1.23 M 1.07 M 1.17 M 1.09 M 1.08 M

General and Administrative Expenses

 		57.9 M 57.9 M 51.7 M 47 M 39.5 M 42.2 M 2.4 M 3.33 M 2.98 M 2.76 M 979 K 1.07 M 1.17 M 1.09 M -

All numbers in USD currency

Quarterly Income Statement LifeMD

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

 		47.8 M 47.3 M 46.2 M 44.4 M 43.1 M 42.2 M 42 M 41.3 M 39.2 M 38.3 M 34.5 M 32.6 M 31.7 M 31.4 M 30.9 M 30.8 M 30.9 M 30.6 M 26.7 M 26.3 M 24.5 M 23.3 M 14.7 M 12.3 M 10.7 M 10.6 M 10.1 M 46.9 M 46.8 M 45.3 M 44.4 M 44.4 M 43.5 M 44 M 40.8 M 40.8 M 37.6 M 35.2 M 34.4 M 32.3 M 32 M 32 M 30.6 M - 30.7 M 30.7 M 30.3 M - 30.2 M 30.1 M 29.4 M 29.2 M 28.9 M 28.9 M 28.9 M 27.6 M 24.7 M - - - -

Net Income

 		-7.08 M -8.87 M -3.81 M -2.07 M 1.38 M - -4.66 M -6.88 M -6.77 M - -6.12 M -6.73 M -4.01 M - -7.28 M -13 M -13.3 M - -14.4 M -17 M -11.9 M - -20.6 M -3.38 M -2.39 M - -944 K -818 K -664 K - -496 K -1.05 M 627 K - -679 K 737 K -1.04 M - -227 K -200 K -62 K - 8.12 K -21 K 1.67 K - -104 K -71.5 K -141 K - -139 K -15.9 K -41.5 K - -159 K -187 K -28.3 K - - - -

Revenue

 		47.3 M 50.2 M 60.2 M 62.2 M 65.7 M - 53.3 M 50.7 M 44.1 M - 38.6 M 35.9 M 33.1 M - 31.4 M 30.5 M 29 M - 24.9 M 22.3 M 18.2 M - 11 M 9.09 M 4.3 M - 3.13 M 2.7 M 2.7 M - 2.5 M 2.04 M 1.61 M - 2.05 M 660 K 5 M - 1.38 M 1.23 M 1.64 M - 280 K 277 K 288 K - 165 K 197 K 192 K - 94.7 K 323 K 230 K - 152 K 228 K 179 K - - - -

Cost of Revenue

 		5.28 M 5.93 M 7.41 M 7.43 M 8.64 M - 5.01 M 5.02 M 4.6 M - 4.78 M 4.55 M 4.21 M - 4.72 M 4.64 M 5.25 M - 5.1 M 4.12 M 3.21 M - 1.68 M 1.69 M 1.34 M - 680 K 655 K 712 K - 440 K 535 K 355 K - 536 K 185 K 88.2 K - 388 K 701 K 1.34 M - 74 K 89.5 K 74.2 K - 71.6 K 69.2 K 49.1 K - 42.4 K 65.7 K 52.9 K - 53.9 K 104 K 29.6 K - - - -

Gross Profit

 		42 M 44.2 M 52.8 M 54.8 M 57.1 M - 48.3 M 45.6 M 39.5 M - 33.8 M 31.4 M 28.9 M - 26.7 M 25.8 M 23.8 M - 19.9 M 18.2 M 15 M - 9.33 M 7.4 M 2.97 M - 2.45 M 2.04 M 1.99 M - 2.06 M 1.5 M 1.25 M - 1.52 M 475 K 79.7 K - 996 K 526 K 303 K - 206 K 188 K 214 K - 93.9 K 127 K 143 K - 52.3 K 257 K 177 K - 98.3 K 124 K 149 K - - - -

Operating Income

 		-7.13 M -8.93 M -1.97 M -907 K 2.54 M - -4 M -6.31 M -6.17 M - -4.57 M -4.9 M -2.85 M - -7.07 M -12.9 M -13.1 M - -12.6 M -16.1 M -11.9 M - -20.5 M -3.22 M -1.74 M - -974 K -833 K -563 K - -386 K -938 K -279 K - -274 K -380 K -402 K - -208 K -154 K -105 K - 17.9 K -17.2 K 7.83 K - -133 K -75.4 K -178 K - -169 K -20.2 K -70.8 K - -164 K -216 K -35.8 K - - - -

Interest Expense

 		-45.7 K -56.5 K 262 K 663 K 626 K - 559 K 531 K 478 K - 714 K 996 K 264 K - 132 K 132 K 168 K - 1.82 M 902 K 139 K - 291 K 229 K 793 K - 131 K 130 K 170 K - 148 K 148 K 6.45 K - 1.11 K 250 649 K - 9.99 K 2.75 K 3.06 K - 14.4 K 8.16 K 10.5 K - 259 428 478 - - - - - - 443 2.93 K - - - -

EBITDA

 		-6.84 M -8.64 M -1.7 M -646 K 2.71 M - -3.75 M -6.06 M -6.11 M - -4.32 M -4.65 M -2.81 M - -6.74 M -12.7 M -13.1 M - -12.6 M -15.9 M -11.8 M - -20.4 M -3.13 M -1.66 M - -890 K -749 K -479 K - -344 K -938 K -279 K - -274 K -380 K -402 K - -208 K -154 K -105 K - 61.7 K 11.3 K 22.1 K - -90.2 K -46.9 K -163 K - -126 K 8.33 K -56.5 K - -121 K -187 K -21.7 K - - - -

Operating Expenses

 		49.1 M 53.2 M 54.7 M 55.7 M 54.5 M - 52.3 M 51.9 M 45.7 M - 38.4 M 36.3 M 31.8 M - 33.8 M 38.7 M 36.9 M - 32.4 M 34.3 M 26.9 M - 29.9 M 10.6 M 4.71 M - 3.42 M 2.88 M 2.55 M - 2.44 M 2.44 M 1.53 M - 1.79 M 855 K 482 K - 1.2 M 680 K 408 K - 188 K 205 K - - - - - - - - - - - - - - - - -

General and Administrative Expenses

 		13.6 M 15.2 M 16.6 M 10.9 M 17.1 M - 18.1 M 8.24 M 15.3 M - 13.4 M 12.1 M 10.6 M - 12.4 M 13.2 M 12.2 M - 10.7 M 20.9 K 7.02 M - 18.4 M 1.83 M 1.59 M - 929 K 373 K 478 K - 301 K 301 K 357 K - 278 K 319 K 108 K - 205 K 79.5 K 98.4 K - 57.6 K 63.9 K 85.3 K - 43.3 K 62.8 K 102 K - 98.7 K 82.3 K 81.5 K - 85.4 K 89.1 K 90.8 K - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements LifeMD LFMD
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting LifeMD plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Pharmaceutical retailers industry

Issuer Price % 24h Market Cap Country
111 111
YI
 		$ 2.96 3.5 % $ 515 M chinaChina
China Jo-Jo Drugstores, Inc. China Jo-Jo Drugstores, Inc.
CJJD
 		- -5.59 % $ 49.9 M chinaChina
Trxade Group Trxade Group
MEDS
 		- 4.55 % $ 5.8 M usaUSA
Аптеки 36.6 Аптеки 36.6
APTK
 		- - - russiaRussia
Rite Aid Corporation Rite Aid Corporation
RAD
 		- - $ 35.5 M usaUSA
BOQI International Medical BOQI International Medical
BIMI
 		- 6.33 % $ 5.86 M chinaChina
Walgreens Boots Alliance Walgreens Boots Alliance
WBA
 		- - $ 10.3 B usaUSA
Greenlane Holdings Greenlane Holdings
GNLN
 		$ 1.88 -2.34 % $ 14.1 M usaUSA
PetMed Express PetMed Express
PETS
 		$ 1.18 -3.28 % $ 24.7 M usaUSA